Circulating adropin levels in patients with endometrium cancer. (2nd September 2015)

• Record Type: Journal Article
• Authors: Nergiz, Sümeyra; Altinkaya, Sunduz Ozlem; Kurt Ömürlü, İmran; Yuksel, Hasan; Küçük, Mert; Demircan Sezer, Selda
• Is Part Of: Gynecological endocrinology. Volume 31:Number 9(2015:Sep.)
• Page Start: 730
• Page End: 735
• Publication Date: 2015-09-02
• Subjects: Adropin -- endometrium cancer -- obesity; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.3109/09513590.2015.1065480
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: Aim : Adropin is a recently identified protein in liver, brain and many peripheral tissues, which is important in energy homeostasis. The purpose of this study is to determine adropin levels in patients with endometrium cancer (EC). Material and methods : A total of 74 patients (47 EC patients and 27 healthy controls) were included in the study. Fasting venous blood samples were collected from all patients. Serum adropin levels were measured by an enzyme-linked immunosorbent assay (ELISA). The correlations between serum adropin levels and clinicopathologic variables were determined. Results : In body mass index and age-matched groups of patients, adropin levels were determined lower in patients with EC than control group ( p < 0.01). Adropin levels were negatively correlated with age ( r = −0.265, p = 0.023), homeostasis model-resistance index (HOMA-IR) ( r = −0.294, p = 0.005) and fasting insulin levels ( r = −0.292, p = 0.001). It was shown that in receiver operator characteristic (ROC) analysis, at cut-off value ≤ 1.055 (ng/ml), adropin had 92.7% sensitivity, 91.5% specificity and had AUC = 0.948, CI; 0.894–1.000 for diagnosis of EC ( p < 0.001). Conclusion : Adropin seems to be an important protein in pathogenesis of EC. Clearly, there are largely unknown aspects of adropin in EC pathophysiology and require further multi-centered, molecular and genetic studies including high number of cases. Chinese abstract: 目的：能量相关蛋白是新近在肝，脑和许多外周组织中被发现的对能量平衡具有重要作用的蛋白质。研究的目的在于确定子宫内膜癌（EC）患者的能量相关蛋白水平。 材料与方法：总计74名患者（47例EC患者和27例对照）被纳入了此项研究。提取所有受试患者的空腹静脉血样本。使用酶联免疫吸附试验（ELISA）测量血清能量相关蛋白水平。评估血清能量相关蛋白水平与临床病理变化之间的联系。 结果：在体质指数和年龄相当的患者组中，EC患者的能量相关蛋白水平较对照组低(p<0.01)。能量相关蛋白水平与年龄(r=－0.265, p=0.023)，稳态模型-抵抗指数(r=－0.294, p=0.005)和空腹胰岛素水平呈负相关(r=－0.292, p=0.001)。受试者工作特征分析表现，在截断值≤1.055 (ng/ml)时，能量相关蛋白在诊断EC时具有92.7% 的灵敏度， 91.5% 的特异性，且 AUC=0.948, CI; 0.894–1.000。 结论：能量相关蛋白是一个对EC的发病机理起重要作用的蛋白质。很明显，能量相关蛋白在EC发病机制中的作用有许多未知的方面，需要进一步的纳入大量患者的多中心的，分子与遗传方面的研究。